Pros | ![]() Lower expense ratio. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | ![]() 3Y returns in the bottom 25% of the category. | - |
INDMoney rank | 5/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 6 Years | ||
Fund Size | 2667 Cr | 4915 Cr | ||
Min Investment | SIP ₹99 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.61% | 1.18% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 34 | 45 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.9%) Aurobindo Pharma Ltd (7.12%) Cipla Ltd (6.91%) Divi's Laboratories Ltd (6.6%) Lupin Ltd (6.2%) | Sun Pharmaceuticals Industries Ltd (13.5%) Dr Reddy's Laboratories Ltd (8.95%) Cipla Ltd (8.85%) Divi's Laboratories Ltd (6.71%) Aurobindo Pharma Ltd (5.3%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (98.7%) Basic Materials (1.3%) Industrial (0%) | Health (90.94%) Basic Materials (6.08%) Financial Services (2.97%) | ||
Equity % | 99.55% | 98.28% | ||
Debt % | - | - | ||
P/E | 34.28 | 28.98 | ||
P/B | 5.04 | 4.16 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.34% | 3.78% | ||
3-Month Return | 5.22% | 4.64% | ||
6-Month Return | -2.93% | -1.46% | ||
1-Year Return | 19.91% | 23% | ||
3-Year Return | 20.32% | 25.34% | ||
5-Year Return | 24.25% | 26.3% |
Sharpe | 0.76 | 1 | ||
Alpha | -0.36 | 3.61 | ||
Beta | 0.98 | 0.93 | ||
Standard Deviation | 17.14 | 16.26 | ||
Information Ratio | -0.24 | 1.05 |
Description | Mirae Asset Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Vrijesh Kasera | Dharmesh Kakkad |